Amyloidosis treatment has evolved significantly in recent years, bringing new hope to people living with this complex group of diseases. From approved medications that target abnormal protein production to cutting-edge therapies being tested in clinical trials around the world, the landscape of care continues to expand. Understanding your treatment options — both established and experimental — can help you and your healthcare team make informed decisions about managing this rare condition.

How Treatment Approaches Are Tailored to Your Disease

Treatment for amyloidosis isn’t one-size-fits-all. The approach your medical team recommends depends heavily on which type of amyloidosis you have, which organs are affected, and how far the disease has progressed. The main goal is to stop the production of abnormal proteins that form amyloid fibrils — sticky clumps that deposit in your organs and tissues. By reducing or halting this protein buildup, treatment can help protect your organs from further damage, ease symptoms like fatigue and shortness of breath, and improve your overall quality of life.^[1][2]

Medical societies and expert centers recognize that timing matters enormously in amyloidosis care. Early diagnosis and aggressive intervention are essential because once amyloid deposits cause significant organ damage, reversing that harm becomes much more difficult. For this reason, healthcare providers emphasize starting treatment as soon as symptomatic organ involvement is confirmed — whether that’s your heart, kidneys, liver, nerves, or digestive system.^[12]

The type of amyloid protein involved makes a big difference in how doctors approach treatment. For example, AL amyloidosis (caused by abnormal light chain proteins from plasma cells) requires different therapies than ATTR amyloidosis (caused by transthyretin protein made by the liver) or AA amyloidosis (linked to chronic inflammation). Knowing your specific diagnosis is the foundation of effective care.^[4][8]

Standard Treatment Options for Amyloidosis

For the most common form of the disease, AL amyloidosis, the current standard first-line treatment is a combination regimen known as daratumumab plus hyaluronidase with cyclophosphamide, bortezomib, and dexamethasone. This combination, sometimes abbreviated as D-VCd or DaraCyborD, represents the first and only therapy specifically approved by the U.S. Food and Drug Administration for newly diagnosed AL amyloidosis.^[12][9]

Daratumumab is a monoclonal antibody — a laboratory-made protein that helps your immune system recognize and attack the abnormal plasma cells that produce harmful light chain proteins. It targets a marker called CD38 found on the surface of these cells. By eliminating the source of the problem, daratumumab helps reduce the production of amyloid-forming proteins. The medication is given as a subcutaneous injection combined with hyaluronidase, which helps the drug absorb into your body more easily.^[12]

This combination therapy works alongside other powerful medications. Bortezomib is a proteasome inhibitor that interferes with the machinery inside plasma cells, causing them to die. Cyclophosphamide is a type of chemotherapy drug that damages the DNA of rapidly dividing cells, including the abnormal plasma cells. Dexamethasone is a steroid that has multiple effects, including reducing inflammation and directly killing plasma cells when used at high doses.^[12]

The goal of this treatment is to achieve what doctors call a “very good partial response” or ideally a “complete hematologic response.” A complete response means that the difference between involved and uninvolved free light chains in your blood is less than 10 mg/L, or the involved light chain level is below 20 mg/L. Achieving this level of response is important because it means the treatment has successfully reduced the production of harmful proteins, giving your organs a chance to recover.^[12][9]

Treatment is typically given in cycles, usually lasting about four to six cycles. If you’re not showing adequate response by cycle two or three, your doctor may modify the treatment plan. Regular monitoring through blood tests helps your healthcare team track how well the therapy is working.^[12]

For select patients with AL amyloidosis who meet specific eligibility criteria, autologous stem cell transplantation (ASCT) may be an option. This intensive procedure involves collecting your own blood-forming stem cells, then giving you high-dose chemotherapy (usually melphalan) to eliminate the abnormal plasma cells, followed by returning your collected stem cells to help your bone marrow recover. Not everyone is eligible for this approach — you generally need to be under age 70, have adequate heart and lung function, and not have severe organ damage.^[12][10]

The decision to undergo stem cell transplantation is complex. While it can produce deep responses in some patients, it carries risks including serious infections, bleeding, and organ complications during the recovery period. Some patients receive drug therapy first and consider transplant if they have an incomplete response, while others may undergo transplant earlier in their treatment journey. The choice depends on your individual health status, organ function, and disease characteristics.^[10]

For AA amyloidosis, which develops in people with chronic inflammatory conditions like rheumatoid arthritis or inflammatory bowel disease, the primary treatment focuses on controlling the underlying inflammatory disease. When the chronic inflammation is brought under control with appropriate medications — such as biologics for rheumatoid arthritis or treatments for chronic infections — the liver produces less serum A protein, which can slow or stop amyloid deposits from forming.^[2][3]

For ATTR amyloidosis, especially the hereditary form, treatment approaches differ. Medications like tafamidis and diflunisal work by stabilizing the transthyretin protein, preventing it from misfolding and forming amyloid fibrils. Gene-silencing therapies such as patisiran and inotersen reduce the production of transthyretin protein by targeting the genetic instructions in liver cells. In some cases of hereditary ATTR amyloidosis, liver transplantation may be considered because the liver produces the abnormal transthyretin protein.^[6]

Throughout treatment, supportive care plays a crucial role. This may include medications to manage heart failure symptoms (like diuretics to reduce fluid buildup), treatments for neuropathy pain, nutritional support, and careful monitoring of kidney function. Because amyloidosis can affect multiple organ systems, you may work with a team of specialists including cardiologists, nephrologists, neurologists, and hematologists.^[1][7]

Innovative Therapies Being Tested in Clinical Trials

Clinical trials are exploring numerous promising new approaches to treating amyloidosis. These studies are essential for expanding treatment options, especially for people whose disease doesn’t respond adequately to standard therapies or who experience relapses after initial treatment.^[9]

One exciting area of research involves venetoclax, a medication that targets a specific genetic abnormality called t(11;14). This chromosomal translocation is found in some patients with AL amyloidosis. Venetoclax works as a BCL-2 inhibitor, meaning it blocks a protein that helps cancer cells survive, essentially forcing the abnormal plasma cells to die. Early studies suggest that patients with t(11;14) may respond particularly well to venetoclax-based treatment combinations. This represents a move toward more personalized therapy based on the molecular characteristics of your disease.^[12][9]

Another novel approach being studied is chimeric antigen receptor T-cell therapy, commonly known as CAR T-cell therapy. This cutting-edge treatment involves collecting your own immune T cells, genetically engineering them in a laboratory to recognize and attack plasma cells bearing a specific marker called BCMA (B-cell maturation antigen), and then infusing these modified cells back into your body. Results from early-phase clinical trials have been encouraging, with some patients achieving deep and durable responses. CAR T-cell therapy targeting BCMA has shown promise in treating relapsed or refractory AL amyloidosis — meaning cases where previous treatments haven’t worked or the disease has come back.^[13][9]

Researchers are also investigating ixazomib, an oral proteasome inhibitor similar to bortezomib but taken as a pill rather than an injection. The convenience of an oral medication could improve quality of life for patients, and studies are examining whether it’s as effective as injected options. Phase 2 and Phase 3 trials are evaluating ixazomib in various combinations for both newly diagnosed and relapsed AL amyloidosis.^[12]

For patients with relapsed or refractory disease, clinical trials are testing several other targeted agents. These include drugs like selinexor, which works by blocking the export of certain proteins from the nucleus of cancer cells, and various immunotherapy combinations that aim to harness the body’s immune system to fight the disease more effectively.^[9]

Many of these clinical trials are being conducted at specialized amyloidosis treatment centers in the United States, Europe, and other regions around the world. To be eligible for a trial, you typically need to meet specific criteria regarding your disease stage, organ function, previous treatments, and overall health status. Your doctor can help you explore whether you’re a candidate for any ongoing trials that might be appropriate for your situation.^[9]

Researchers are also working on therapies designed to actually remove existing amyloid deposits from organs, not just stop new deposits from forming. These experimental approaches include antibodies that target and clear amyloid fibrils, as well as small molecules that might help break down existing deposits. While these treatments are still in early research stages, they represent an important frontier in amyloidosis care.^[6]

Most common treatment methods

• Chemotherapy and immunosuppressive drugs
  • Daratumumab with cyclophosphamide, bortezomib, and dexamethasone (DaraCyborD) for AL amyloidosis — the FDA-approved first-line standard treatment combination
  • Melphalan and dexamethasone combinations — older chemotherapy regimens still used in some settings
  • High-dose melphalan followed by autologous stem cell transplant for eligible patients with AL amyloidosis
• Targeted therapy
  • Bortezomib (proteasome inhibitor) — disrupts plasma cell function and causes cell death
  • Venetoclax (BCL-2 inhibitor) — especially promising for patients with t(11;14) genetic abnormality
  • Ixazomib (oral proteasome inhibitor) — under investigation in clinical trials
• Monoclonal antibody therapy
  • Daratumumab — targets CD38 on plasma cells to eliminate abnormal protein production
• Protein stabilizers and gene silencers (for ATTR amyloidosis)
  • Tafamidis and diflunisal — stabilize transthyretin protein to prevent misfolding
  • Patisiran and inotersen — reduce liver production of transthyretin protein through gene silencing
• Immunotherapy
  • CAR T-cell therapy targeting BCMA — genetically modified immune cells that attack plasma cells, being studied in clinical trials for relapsed/refractory AL amyloidosis
• Transplantation
  • Autologous stem cell transplantation — for eligible AL amyloidosis patients with adequate organ function
  • Liver transplantation — may be considered for hereditary ATTR amyloidosis in select cases
  • Heart or kidney transplantation — in cases of severe organ damage, sometimes performed before or after amyloidosis-specific treatment
• Treatment of underlying conditions (for AA amyloidosis)
  • Biologics and disease-modifying drugs for rheumatoid arthritis or inflammatory bowel disease
  • Antibiotics or other treatments for chronic infections